Olmesartan Medoxomilo + Hidroclorotiazida Alter (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Alter, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is prescribed for adults. GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to lower blood pressure. Indicated indications include: - Hypertension: improves blood pressure control when monotherapy is insufficient. - Hypertensive urgency: assists in achieving target pressures more rapidly under medical supervision. - Diastolic heart failure with fluid overload: reduces preload and afterload, aiding symptom management. - Chronic kidney disease with hypertension: slows progression by controlling systemic pressure. - Post‑myocardial infarction hypertension: helps maintain optimal hemodynamics after an event.

Olmesartan medoxil with hydrochlorothiazide may cause a range of adverse reactions.

Common Side Effects: - Dizziness: light‑headed sensation, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Electrolyte imbalance: low potassium or sodium levels. - Increased urination: due to the diuretic component. - Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated potassium levels, potentially life‑threatening. - Angioedema: swelling of face, lips, tongue, or airway. - Liver enzyme elevation: signs of hepatic stress. - Blood dyscrasias: rare blood cell abnormalities.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: check serum potassium and sodium before and during treatment. - Pregnancy: avoid use; teratogenic risk is documented for ARBs. - Concomitant drugs: review for additive potassium‑sparing or diuretic effects. - Elderly patients: start with lower dose and monitor for orthostatic changes. - Store at below 25°C: keep in the original container, protect from moisture and light.

Olmesartan medoxil with hydrochlorothiazide can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Aliskiren: combined use in diabetes or renal impairment may increase risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyper‑kalemia. - NSAIDs: can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, risking toxicity. - Antidiabetic agents: enhanced glucose‑lowering effect may require dose adjustment. - ACE inhibitors or other ARBs: additive blood pressure lowering and renal risk. - Loop diuretics: may intensify volume depletion and electrolyte disturbances. - Antidepressants (SSRIs): modest increase in hyponatremia risk.